Article Details
Retrieved on: 2017-12-20 00:07:30
Tags for this article:
Click the tags to see associated articles and topics
Excerpt
<div>Private biotech Galera Therapeutics Inc. on Monday said a Phase 2b study of its lead drug candidate succeeded, showing the experimental treatment reduced the duration of severe oral mucositis in certain cancer patients compared to those receiving placebo. Severe oral mucositis, or SOM, is a ...</div>
Article found on:
This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.
Sign UpAlready have an account? Log in here